Cardio Diagnostics (NASDAQ:CDIO) Posts Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) issued its earnings results on Friday. The company reported ($0.80) EPS for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 39,674.18% and a negative return on equity of 67.51%.

Cardio Diagnostics Price Performance

Shares of NASDAQ CDIO traded down $1.76 during mid-day trading on Friday, reaching $2.80. 1,127,513 shares of the company’s stock traded hands, compared to its average volume of 10,924,570. The business has a 50-day simple moving average of $2.68 and a 200 day simple moving average of $3.33. The stock has a market cap of $5.12 million, a P/E ratio of -0.75 and a beta of 2.28. Cardio Diagnostics has a 1-year low of $0.97 and a 1-year high of $17.39.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.